The current study adds to the growing literature on HIV+ hemophiliacs and cognition in the cART era and was strengthened by selective inclusion criteria (such as the level of CD4 >200, the absence of a psychiatric disorder, such as a diagnosis of depression/anxiety), thereby allowing the evaluation of a precise and representative cohort. This evidence concerns the gene CD4 and depressive symptom measurement.